Immuno Oncology (I-O) Market Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types - Global Forecast to 2026

Pages: 209 | Published Date: October 2020 | Report ID: 4106 Sectors , ,

From $2,990.00

  • Single User
  • Multi User
  • Corporate User
Clear

COVID-19

As Covid-19 outbreak has major economical impact on global business. Get the detailed insight about COVID-19 impression on your business...

REPORT DESCRIPTION

Global Immuno Oncology Market is valued at 12.80 USD Billion in 2019 and expected to reach USD 49.13 Billion by 2026 with the CAGR of 21.19% over the forecast period.

Scope of the report
This report analyses the global market for Immuno Oncology. The report will enable the user to understand and gain insights into the current and forecast market situation. The market is comprehensively analyzed by geography to give complete information on the global scenario. The qualitative and quantitative data provided in this study can help user understand which market segments, regions are expected to grow at higher rates, factors affecting the market and key opportunity areas. The report also includes competitive landscape of key players in the industry along with emerging trends in the market.
Key Players
Bristol Myers Squibb, Merck, AstraZeneca, Roche, Pfizer, Incyte and others
Above mentioned companies were scrutinized to assess competitive landscape of global Immuno Oncology market. Report provides company profiles of each player. Each profile include company product portfolio,business overview, company governance, company financials, business strategies, manufacturing locations and production facilities, company sale, recent developments and strategic collaborations & partnerships, new product launch, company segments, application diversification and company strength and weakness analysis.
Review period: (2016-2026)
Historic Period: 2016 to 2019
Forecast Period: 2020 to 2026
Base Year: 2019
Unit: USD Billion
This Immuno Oncology market report provides insights on new trade regulations, import export analysis, industry value chain analysis, market size, consumption, production analysis, capacity analysis, regional and segment market share, product launches, product pipeline analysis, impact of Covid-19 on supply chain, key regions, untapped markets, patent analysis, product approvals, continuous innovations and developments in the market.
Regions
• North America: U.S., Canada and Rest of North America
• Europe: UK, France, Germany, Italy, Spain and Rest of Europe
• Asia Pacific: China, Japan, India, Australia, Southeast Asia and Rest of Asia Pacific
• Latin America: Brazil, Mexico, Argentina and Rest of Latin America
• Middle East and Africa: Gulf Countries, Israel, Africa and Rest of Middle East and Africa

Market Segmentation
By Treatment Approaches
• Monoclonal Antibodies
• Therapeutic Vaccines
• Checkpoint Inhibitors
• Cytokines
By Novel Targets
• IDO1i
• LAG-3 CPI
• Oncolytic virus
• STING agonist
• TLR agonist
• HDACi
• TIL
• VEGFi
• MEKi
• TIGIT
• CPI
• GITR agonist
• TGF-b trap
• A2AR antagonist/CD73i
By Tumor Types
• Melanoma
• Non-Small Cell Lung Cancer
• Renal Cell Carcinoma
• Head & Neck Cancer
• Bladder Cancer
• Classical Hodgkin’s Lymphoma
• Merkel Cell Carcinoma
• Others

Report Coverage
• An overview of the global Immuno Oncology market
• In depth analysis of market dynamics and major factors such as drivers, restraints, opportunities and trends influencing the global market
• Global Immuno Oncology market revenue data historic and forecast analysis (2016 to 2026)
• Characterization and quantification of the market segments for Immuno Oncology market
• Market share analysis of key market participants and their competitive landscape
Important Questions Answered by Global Immuno Oncology Market Report
• What is the impact of COVID 19 epidemic on the global Immuno Oncology market?
• Which is mostly affected region, country?
• Which is the current largest and fastest-growing region?
• What is the market size and growth rate of the global Immuno Oncology market?
• What are current factors affecting the growth of market?
• What are Key trends and opportunity areas?
• Within Immuno Oncology market, which segments are fastest growing & emerging strongly? What are the drivers and restraints for each segment? What are vendor competencies by segment?
• What are the major strategies adopted by leading market companies?
• What are company challenges and essential success factors by market segment?
• How company offerings and supply chain capabilities are shifting to meet emerging market needs?

TABLE OF CONTENT

1. Introduction
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
1.4. List of Abbreviations
2. Executive Summary
3. Market Overview
3.1. Market Definition
3.2. Market Scope
3.3. Market Drivers
3.4. Market Restraints
3.5. Market Opportunities and Trends
3.6. Porter’s five force analysis
3.7. SWOT Analysis
3.8. PEST Analysis
3.9. Patent Analysis
3.10. Impact of COVID 19 on Global Immuno Oncology Market
4. Immuno Oncology Market, By Treatment Approaches, Market Size and Forecast 2016 -2026 (USD Billion)
4.1. Global Immuno Oncology Market By Treatment Approaches, 2016 -2026 (USD Billion)
4.1.1. Global Immuno Oncology Market By Monoclonal Antibodies
4.1.2. Global Immuno Oncology Market By Therapeutic Vaccines
4.1.3. Global Immuno Oncology Market By Checkpoint Inhibitors
4.1.4. Global Immuno Oncology Market By Cytokines

4.2. Global Immuno Oncology Market By Treatment Approaches Share, 2016 -2026 (%)

5. Immuno Oncology Market, By Novel Targets, Market Size and Forecast 2016 -2026 (USD Billion)
5.1. Global Immuno Oncology Market By Novel Targets,2016 -2026 (USD Billion)
5.1.1. Global Immuno Oncology Market By IDO1i
5.1.2. Global Immuno Oncology Market By LAG-3 CPI
5.1.3. Global Immuno Oncology Market By Oncolytic virus
5.1.4. Global Immuno Oncology Market By STING agonist
5.1.5. Global Immuno Oncology Market By TLR agonist
5.1.6. Global Immuno Oncology Market By HDACi
5.1.7. Global Immuno Oncology Market By TIL
5.1.8. Global Immuno Oncology Market By VEGFi
5.1.9. Global Immuno Oncology Market By MEKi
5.1.10. Global Immuno Oncology Market By TIGIT
5.1.11. Global Immuno Oncology Market By CPI
5.1.12. Global Immuno Oncology Market By GITR agonist
5.1.13. Global Immuno Oncology Market By TGF-b trap
5.1.14. Global Immuno Oncology Market By A2AR antagonist/CD73i

5.2. Global Immuno Oncology Market By Novel Targets Share, 2016 -2026 (%)
6. Immuno Oncology Market, By Tumor Types, Market Size and Forecast 2016 -2026 (USD Billion)
6.1. Global Immuno Oncology Market By Tumor Types, 2016 -2026 (USD Billion)
6.1.1. Global Immuno Oncology Market By Melanoma
6.1.2. Global Immuno Oncology Market By Non-Small Cell Lung Cancer
6.1.3. Global Immuno Oncology Market By Renal Cell Carcinoma
6.1.4. Global Immuno Oncology Market By Head & Neck Cancer
6.1.5. Global Immuno Oncology Market By Bladder Cancer
6.1.6. Global Immuno Oncology Market By Classical Hodgkin’s Lymphoma
6.1.7. Global Immuno Oncology Market By Merkel Cell Carcinoma and Others

6.2. Global Immuno Oncology Market By Tumor Types Share, 2016 -2026 (%)
7. Immuno Oncology Market, By Region Market Size and Forecast 2016 -2026
7.1. NORTH AMERICA
7.1.1. Key Findings
7.1.2. Impact of COVID 19
7.1.3. Key market trends, growth factors and opportunities
7.1.4. North America Immuno Oncology Market by Country 2016 -2026 (USD Billion)
7.1.5. North America Immuno Oncology Market By Treatment Approaches2016 -2026 (USD Billion)
7.1.6. North America Immuno Oncology Market By Novel Targets 2016 -2026 (USD Billion)
7.1.7. North America Immuno Oncology Market By Tumor Types 2016 -2026 (USD Billion)
7.2. EUROPE
7.2.1. Key Findings
7.2.2. Impact of COVID 19
7.2.3. Key market trends, growth factors and opportunities
7.2.4. Europe Immuno Oncology Market by Country 2016 -2026 (USD Billion)
7.2.5. Europe Immuno Oncology Market By Treatment Approaches 2016 -2026 (USD Billion)
7.2.6. Europe Immuno Oncology Market By Novel Targets 2016 -2026 (USD Billion)
7.2.7. Europe Immuno Oncology Market By Tumor Types 2016 -2026 (USD Billion)
7.3. ASIA PACIFIC
7.3.1. Key Findings
7.3.2. Impact of COVID 19
7.3.3. Key market trends, growth factors and opportunities
7.3.4. Asia Pacific Immuno Oncology Market by Country 2016 -2026 (USD Billion)
7.3.5. Asia Pacific Immuno Oncology Market By Treatment Approaches 2016 -2026 (USD Billion)
7.3.6. Asia Pacific Immuno Oncology Market By Novel Targets 2016 -2026 (USD Billion)
7.3.7. Asia Pacific Immuno Oncology Market By Tumor Types 2016 -2026 (USD Billion)
7.4. LATIN AMERICA
7.4.1. Key Findings
7.4.2. Impact of COVID 19
7.4.3. Key market trends, growth factors and opportunities
7.4.4. Latin America Immuno Oncology Market by Country 2016 -2026 (USD Billion)
7.4.5. Latin America Immuno Oncology Market By Treatment Approaches 2016 -2026 (USD Billion)
7.4.6. Latin America Immuno Oncology Market By Novel Targets 2016 -2026 (USD Billion)
7.4.7. Latin America Immuno Oncology Market By Tumor Types 2016 -2026 (USD Billion)
7.5. MIDDLE EAST AND AFRICA
7.5.1. Key Findings
7.5.2. Impact of COVID 19
7.5.3. Key market trends, growth factors and opportunities
7.5.4. Middle East and Africa Immuno Oncology Market by Country 2016 -2026 (USD Billion)
7.5.5. Middle East and Africa Immuno Oncology Market By Treatment Approaches 2016 -2026 (USD Billion)
7.5.6. Middle East and Africa Immuno Oncology Market By Novel Targets 2016 -2026 (USD Billion)
7.5.7. Middle East and Africa Immuno Oncology Market By Tumor Types 2016 -2026 (USD Billion)
8. Competitive Landscape Analysis
8.1. Global Immuno Oncology Market Company Revenue, (USD Billion), 2016-2019
8.2. Global Immuno Oncology Market Company Share, (%), 2016-2019
9. Company Profiles
9.1. Bristol Myers Squibb
9.2. Merck
9.3. AstraZeneca
9.4. Roche
9.5. Pfizer
9.6. Incyte
9.7. Others
10. Appendix
11. List of Tables
12. List of Figures

Name
Email
Phone
Enquiry

Request Free Sample Report